We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter takes public health, primary care, general adult psychiatry, and liaison perspectives to address the challenges of self-harm and suicide in older people. We focus on key differences – in epidemiology (social circumstances, methods, repetition of self-harm), outcomes, and antecedents (poor physical health, loss of autonomy, cognitive impairment) – between this group and the rest of the adult population. In the prevention of suicide, we recommend a life-course, transdiagnostic approach, and in particular a proactive treatment of depression. In emergency room settings, multiple sources of information over time improve assessment – then a holistic approach to interventions. We identify four higher-risk subgroups and set out mitigating interventions. Among the four, older psychiatric in-patients qualify for safer wards and safe discharge planning. An additional and related group is identified: carers of older people with combined physical and mental comorbidities, who have higher levels of suicidal ideation but do not disclose them. When the worst outcome – suicide – occurs, there are evidence-based interventions (now called ’postventions’).
This perspective article applies public health principles to improve the physical health of selected populations with mental disorders. Two preventable adverse outcomes, poorer physical health and premature mortality, are described across mental disorders. Evidence of the lifetime effects of adverse childhood experiences and inequalities is presented: these are the ‘causes of the causes’. Seven drivers of physical disorders are illustrated that drive preventable deaths and as doctors, psychiatrists must lead from the front to reverse rising mortality. Evidence supports universal and selective interventions and even the most difficult challenges such as weight gain and opioid misuse are an opportunity for psychiatry to engage with individual patients and their organisations, public health colleagues, health systems and beyond. Interventions complement and do not replace existing clinical practices that reduce self-harm and prevent suicide. Mental health teams already do most of the work in this arena, and the case is made to refocus on physical health with task sharing. The top 10 recommendations within a personalised medicine framework are listed in this paper as a starting point.
Adults who had non-edematous severe acute malnutrition (SAM) during infancy (i.e., marasmus) have worse glucose tolerance and beta-cell function than survivors of edematous SAM (i.e., kwashiorkor). We hypothesized that wasting and/or stunting in SAM is associated with lower glucose disposal rate (M) and insulin clearance (MCR) in adulthood.
We recruited 40 nondiabetic adult SAM survivors (20 marasmus survivors (MS) and 20 kwashiorkor survivors (KS)) and 13 matched community controls. We performed 150-minute hyperinsulinaemic, euglycaemic clamps to estimate M and MCR. We also measured serum adiponectin, anthropometry, and body composition. Data on wasting (weight-for-height) and stunting (height-for-age) were abstracted from the hospital records.
Children with marasmus had lower weight-for-height z-scores (WHZ) (−3.8 ± 0.9 vs. −2.2 ± 1.4; P < 0.001) and lower height-for-age z-scores (HAZ) (−4.6 ± 1.1 vs. −3.4 ± 1.5; P = 0.0092) than those with kwashiorkor. As adults, mean age (SD) of participants was 27.2 (8.1) years; BMI was 23.6 (5.0) kg/m2. SAM survivors and controls had similar body composition. MS and KS and controls had similar M (9.1 ± 3.2; 8.7 ± 4.6; 6.9 ± 2.5 mg.kg−1.min−1 respectively; P = 0.3) and MCR. WHZ and HAZ were not associated with M, MCR or adiponectin even after adjusting for body composition.
Wasting and stunting during infancy are not associated with insulin sensitivity and insulin clearance in lean, young, adult survivors of SAM. These data are consistent with the finding that glucose intolerance in malnutrition survivors is mostly due to beta-cell dysfunction.
1. No one chooses to become an intensive care patient – adjusting well draws both on coping skills and on experienced, empathic staff to help vulnerable people.
2. Anxiety is the norm, not the exception, in a busy, noisy ICU. Even high-standard ICU care can bring back memories of previous bad experiences, especially psychological traumas such as childhood abuse.
3. Early identification of anxiety disorders (including trauma-generated) and multi-level interventions will reduce anxiety amongst patients, their carers and staff.
4. Experienced ICU staff deal with a range of personality traits and diverse reactions to illness. Staff supporting one another is the most effective intervention.
5. Up to 25 per cent of discharged ICU patients have post-traumatic stress disorder (PTSD) symptoms – there are subgroups more likely to get PTSD and minimising ICU benzodiazepine use has been shown to diminish it.
1. The four components of capacity concern a patient’s ability to understand, retain, weigh and communicate a decision.
2. It is the responsibility of the lead clinician to ensure that capacity has been assessed and to make the final decision regarding capacity, even where a professional opinion has been sought.
3. The Mental Capacity Act (MCA) 2005 allows treatment of patients for MEDICAL conditions only, under the ‘best interests’ principle.
4. All patients admitted to the intensive care unit should be considered at risk of deprivation of liberty, and a Deprivation of Liberty Safeguards (DoLS) assessment should be considered.
5. The Mental Health Act (MHA; 1983) allows treatment of patients for PSYCHIATRIC conditions only.
1. All busy hospitals receive violent patients. Staff should be trained in appropriate reduction and response practices. Make the environment as safe as possible, and plan for a ‘worst case scenario’.
2. For patients who understand their behaviours, set limits to expressions of anger. Aggression must not compromise others’ care.
3. Identify specific groups at risk of ‘unpredictable aggression’.
4. Reducing aggression requires: (1) coordinated, multi-level action; (2) treatment of pain, review of medication and safe prescription of sedatives; (3) consistent nursing staff, extra staffing and a multidisciplinary team approach; (4) family involvement; and (5) psychiatric liaison.
5. After violent events, document and report events accurately, and debrief all staff involved.
1. Features of overdose depend on the type of antidepressant or anti-psychotic agent taken.
2. All patients suspected of overdose must be monitored for QRS/QT prolongation.
3. In some overdoses (monoamine oxidase inhibitors, hypoglycaemic agents, long-acting insulin, anticoagulants), onset of symptoms may be delayed; an asymptomatic patient may still require admission and treatment in the intensive care unit.
4. Serotonin syndrome is a medical emergency defined as an adverse reaction to serotonergic agents.
5. Neuroleptic malignant syndrome is a medical emergency caused by an idiosyncratic reaction to neuroleptic medication.
Historical fears of violence by people with mental disorders increased in the final years of the last century. Science demonstrated falling UK homicide rates by people with psychosis but inaccurate perceptions drove UK government policy. As public perception of violence subsides, we see increasing societal narratives of pity for people who lose their mental health; these will mostly serve to extend their exclusion and deepen inequalities. Pity makes people ill. Actions to highlight and reduce stigma and discrimination have softened some attitudes, but mental health awareness is no substitute for actual engagement with people who have mental disorders and sustainable funding for those that need state supports (housing, income) or health services. Clinicians and partners in mental health reform have a duty to engage with local communities (and sometimes beyond) to achieve enough degrees of public engagement to prevent mental disorders by reducing the causes, principally poverty and inequality. These actions are just as important as providing fully integrated community mental health services. Parity of esteem is never having to say you are sorry (for someone) but to collaborate/advocate for their rights.
We examine epidemiological evidence for the central role of inequalities (principally economic) in driving the onset of mental disorders, physical ill health and premature mortality. We locate the search for solutions in current UK contexts, and include known and likely effects of the COVID-19 pandemic. Prevention of mental disorders and adverse outcomes such as premature mortality must begin with efforts to mitigate rising poverty-inequality.
Behavioral and psychological symptoms of dementia (BPSD), constitute a major clinical component of Alzheimer’s disease (AD). There is a growing interest in BPSD as they are responsible for a large share of the suffering of patients and caregivers, and they strongly determine the patient’s lifestyle and management. Better detection and understanding of these symptoms is essential to provide appropriate management. This article is a consensus produced by the behavioral group of the European Alzheimer’s Disease Consortium (EADC). The aim of this article is to present clinical description and biological correlates of the major behavioral and psychological symptomatology in AD. BPSD is not a unitary concept. Instead, it should be divided into several symptoms or more likely: groups of symptoms, each possibly reflecting a different prevalence, course over time, biological correlate and psychosocial determinants. There is some clinical evidence for clusters within groups of BPSD. Biological studies indicate that patients with AD and BPSD are associated with variations in the pathological features (atrophy, brain perfusion/metabolism, histopathology) when compared to people with AD without BPSD. An individually tailored approach taking all these aspects into account is warranted as it may offer more, and better, pharmacological and non-pharmacological treatment opportunities.
Addictions are challenging health and social problems that need to be addressed to preserve and promote good mental health and ensure that individuals within society lead healthy and productive lives. Tackling addictions is complex and requires communities, public health, specialist services, and local and national government to act in unison and implement evidence-based interventions. This editorial raises systemic issues that need attention and proposes a range of systemic options.
The outermost “crust” and an underlying, compositionally distinct, and denser layer, the “mantle,” constitute the silicate portion of a terrestrial planet. The “lithosphere” is the planet’s high-strength outer shell. The crust records the history of shallow magmatism, which along with temporal changes in lithospheric thickness, provides information on a planet’s thermal evolution. We focus on the basic structure and mechanics of Mercury’s crust and lithosphere as determined primarily from gravity and topography data acquired by the MESSENGER mission. We first describe these datasets: how they were acquired, how the data are represented on a sphere, and the limitations of the data imparted by MESSENGER’s highly eccentric orbit. We review different crustal thickness models obtained by parsing the observed gravity signal into contributions from topography, relief on the crust–mantle boundary, and density anomalies that drive viscous flow in the mantle. Estimates of lithospheric thickness from gravity–topography analyses are at odds with predictions from thermal models, thus challenging our understanding of Mercury’s geodynamics. We show that, like those of the Moon, Mercury's ellipsoidal shape and geoid are far from hydrostatic equilibrium, possibly the result of Mercury's peculiar surface temperature distribution and associated buoyancy anomalies and thermoelastic stresses in the interior.
Major depression is a complex disorder with no single, direct causal mechanism. Morbidity has been linked to genetic processes, developmental history, and unique environmental exposures. Epigenetic mechanisms, especially DNA methylation, are also likely important factors in the pathogenesis of major depressive disorder (MDD). A community-based twin sample has many advantages for epigenetic studies, given the shared genetic and developmental histories of same-sex twin pairs. This article describes the rationale and study design for the Mood and Methylation Study in which 133 twin pairs (101 monozygotic and 32 dizygotic), both discordant and concordant for lifetime history of MDD, were evaluated on a large number of variables related to MDD. The twins also provided blood samples for an epigenome-wide association study of differentially methylated regions (DMR) relevant to MDD. Although MDD is typically considered a disorder of the central nervous system, it is unfeasible to obtain a large sample of brain tissues. However, epigenetic variation is not limited to the affected tissue but can also be detected in peripheral blood leukocytes. Thus, this study focused on monocytes for the major analyses. Additional plans for the study include gene expression analysis from the same set of twins using RNA-seq and validation of significant DMRs in postmortem brain tissues from a separate sample. Moreover, sufficient samples have been collected to perform future ‘multi-omic’ analyses, including metabolome, microbiome, and transcriptome. Our long-term goal is to understand how epigenomic and other ‘omic’ factors can be manipulated for diagnostic, preventive, and therapeutic purposes for MDD and its related conditions.
Better indicators of prognosis are needed to personalise post-traumatic stress disorder (PTSD) treatments.
Aims
We aimed to evaluate early symptom reduction as a predictor of better outcome and examine predictors of early response.
Method
Patients with PTSD (N = 134) received sertraline or prolonged exposure in a randomised trial. Early response was defined as 20% PTSD symptom reduction by session two and good end-state functioning defined as non-clinical levels of PTSD, depression and anxiety.
Results
Early response rates were similar in prolonged exposure and sertraline (40 and 42%), but in sertraline only, early responders were four times more likely to achieve good end-state functioning at post-treatment (Number Needed to Treat = 1.8, 95% CI 1.28–3.00) and final follow-up (Number Needed to Treat = 3.1, 95% CI 1.68–16.71). Better outcome expectations of sertraline also predicted higher likelihood of early response.
Conclusions
Higher expectancy of sertraline coupled with early response may produce a cascade-like effect for optimal conditions for long-term symptom reduction. Therefore, assessing expectations and providing clear treatment rationales may optimise sertraline effects.
Currently it is estimated that about 1 billion people globally have non-alcoholic fatty liver disease (NAFLD), a condition in which liver fat exceeds 5 % of liver weight in the absence of significant alcohol intake. Due to the central role of the liver in metabolism, the prevalence of NAFLD is increasing in parallel with the prevalence of obesity, insulin resistance and other risk factors of metabolic diseases. However, the contribution of liver fat to the risk of type 2 diabetes mellitus and CVD, relative to other ectopic fat depots and to other risk markers, is unclear. Various studies have suggested that the accumulation of liver fat can be reduced or prevented via dietary changes. However, the amount of liver fat reduction that would be physiologically relevant, and the timeframes and dose–effect relationships for achieving this through different diet-based approaches, are unclear. Also, it is still uncertain whether the changes in liver fat per se or the associated metabolic changes are relevant. Furthermore, the methods available to measure liver fat, or even individual fatty acids, differ in sensitivity and reliability. The present report summarises key messages of presentations from different experts and related discussions from a workshop intended to capture current views and research gaps relating to the points above.
Symptoms of anxiety relating to Parkinson's disease (PD) occur commonly and include symptomatology associated with motor disability and complications arising from PD medication. However, there have been relatively few attempts to profile such disease-specific anxiety symptoms in PD. Consequently, anxiety in PD is underdiagnosed and undertreated. The present study characterizes PD-related anxiety symptoms to assist with the more accurate assessment and treatment of anxiety in PD.
Methods:
Ninety non-demented PD patients underwent a semi-structured diagnostic assessment targeting anxiety symptoms using relevant sections of the Mini International Neuropsychiatric Interview (MINI-plus). In addition, they were assessed for the presence of 30 PD-related anxiety symptoms derived from the literature, the clinical experience of an expert panel and the PD Anxiety-Motor Complications Questionnaire (PDAMCQ). The onset of anxiety in relation to the diagnosis of PD was determined.
Results:
Frequent (>25%) PD-specific anxiety symptoms included distress, worry, fear, agitation, embarrassment, and social withdrawal due to motor symptoms and PD medication complications, and were experienced more commonly in patients meeting DSM-IV criteria for an anxiety disorder. The onset of common anxiety disorders was observed equally before and after a diagnosis of PD. Patients in a residual group of Anxiety Not Otherwise Specified had an onset of anxiety after a diagnosis of PD.
Conclusion:
Careful characterization of PD-specific anxiety symptomatology provides a basis for conceptualizing anxiety and assists with the development of a new PD-specific measure to accurately assess anxiety in PD.